Healthcare Industry News: S.A.
News Release - December 28, 2007
CytoCore Names President, International Operations
CHICAGO--(HSMN NewsFeed)--CytoCore Inc. (OTCBB:CYOE ), the biopharmaceutical reS.A.ch and medical device company for early detection and treatment of reproductive-tract cancers, announced today the appointment of Augusto Ocana, MD, JD as President, International Operations.Dr. Ocana has extensive experience in the global pharmaceutical and medical device industries. His career S.A.s over 20 years leading both S.A.t-up and mature, multi-billion dollar companies. Ocana has subS.A.tial expertise in distribution, strategic partnering, and business development.
“Dr. Ocana’s wealth of experience in the medical productS.A.ena on virtually every continent will be a great asset as CytoCore becomeS.A.truly global organization,” said Chief Executive Officer Robert McCullough, Jr. "Dr. Ocana played a pivotal role in eS.A.lishing our first three distributor relationships in Europe and is working toward completing our European and Latin American distribution networks."
Ocana's has been associated with CytoCore for over a year. Prior to joining CytoCore, his previous positions include senior vice president and managing director at CH-Werfen, S.A., a $1 billion medical reS.A.ch and device company. He has served in leadership roles with major pharmaceutical and diagnostic giants such as Group Taper, S.A., and Abbott Laboratories, Inc. He haS.A.so served on the board of directors of major health care companies.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be used in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The CytoCore Solutions(tm) System is being developed to provide medical practitioners with highly accurate, cost-effective cancer screening systems that can be S.A.lessly integrated into existing medical models. More information iS.A.ailable at: www.CytoCoreInc.com
Certain S.A.ements in this release are forward-looking. These S.A.ementS.A.e based on CytoCore's current expectationS.A.d involve many riskS.A.d uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not subS.A.tiate CytoCore's expectations with respect to the CytoCore Solutions™ System, and other factors set forth in reportS.A.d documents filed by CytoCore with the SecuritieS.A.d Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factorS.A.fecting the Company's business. These factors include, among others, riskS.A.d uncertainties detailed in the Company's periodic public filings with the SecuritieS.A.d Exchange Commission, including but not limited to the Company'S.A.nual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking S.A.ements contained herein.
Source: CytoCore
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!